ARYX THERAPEUTICS (NASDAQ:ARYX)
2.46
+0.03 (1.23%)
| ARYX THERAPEUTICS (NASDAQ:ARYX) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $2.43 | 52 Week High | $6.32 | ||
| Open | $2.43 | 52 Week Low | $1.10 | ||
| Day High | $2.50 | P/E | N/A | ||
| Day Low | $2.40 | EPS | $-1.62 | ||
| Volume | 76,043 | ||||
| More ARYX Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| MRNA | 2 | NTWK | 2 |
| TRGT | 2 | SMOD | 2 |
| PFE | 2 | AMGN | 2 |
| TTWO | 2 | AXL | 2 |
| AUXL | 2 | AZN | 2 |
| CPY | 2 | GM | 1 |
Entities who have mentioned ARYX
- StreetInsider.com Morning Movers | View Related Stories »
- Bankruptcy | View Related Stories »
- Robert W Baird | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Initial Jobless Claims | View Related Stories »
- Trading Radar | View Related Stories »
- Needham & Co | View Related Stories »
- Piper Jaffray | View Related Stories »
- David Faber | View Related Stories »
- Dividend | View Related Stories »
- Jefferies & Co | View Related Stories »
- Rodman & Renshaw | View Related Stories »
- Morgan Keegan & Company | View Related Stories »
- Crude Oil | View Related Stories »
StreetInsider.com Major News for ARYX
View All ReportsStreetInsider.com Reports on ARYX
- ARYx Therapeutics (ARYX) Announces Results from PASCAL Phase 2b
- ARYx Therapeutics (ARYX) Experiences a Q3 Loss of $0.30, Misses Views
- Trading Radar for 11/12: Wal-Mart (WMT), Blockbuster (BBI), Nordstrom (JWN), Walt Disney (DIS), Kohl's (KSS) Report
- $35MM Financing Facility Secured by ARYx Therapeutics (ARYX)
- Unusual 11 Mid-Day Movers 7/8: NVGN, GRVY, TRGT, AMGN Higher; ARYX, RODM, YRCW, GNW Lower
View All Press ReleasesCompany Press Releases on ARYX
- Results From Phase 2b Study on Atrial Fibrillation Agent Reviewed at American Heart Association
- ARYx Therapeutics Reports Third Quarter 2009 Results
- ARYx Therapeutics Schedules Third Quarter 2009 Results Conference Call
- ARYx to Present at the Oppenheimer Annual Healthcare Conference
- ARYx Therapeutics Aligns Operations to Development Activities
StreetInsider Reports on ARYX by Category
View All BlogsBlogs on ARYX
- Biotech Tribulations Roundup: Failed Trials, Missed Targets, Business Mishaps
- Closing Update for Wednesday July 8
- Extreme FDA Trades: Another 18 Stocks Under 5 Bucks
- Big Lineup of Healthcare Stocks Crack the Russell 3000 Index
- FDA Calendar Updates: BioDelivery Sciences Worth the Wait
Comments on ARYX
No comments are currently available.
